535 results on '"Reiffers, Josy"'
Search Results
52. Flow Cytometry Study of Human Cyclin B1 and Cyclin E Expression in Leukemic Cell Lines: Cell Cycle Kinetics and Cell Localization
53. LEUKAEMIA INHIBITORY FACTOR EXPRESSION IS INHIBITED BY GLUCOCORTICOIDS THROUGH POST-TRANSCRIPTIONAL MECHANISMS
54. Expression of Neurotrophins and their Receptors in Human Bone Marrow
55. La Fédération devient française et lance officiellement le Groupe UNICANCER
56. Les cibles intracytoplasmiques Ed. 1
57. MATWIN: bridging the gap between academic research and industry
58. Pro-survival role of p62 during granulocytic differentiation of acute myeloid leukemia cells
59. ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
60. Reply to J. Richter et al
61. Professeur John M. Goldman 1938-2013
62. Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
63. Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease
64. ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?
65. Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study
66. Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.
67. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
68. Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy
69. Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
70. Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study
71. Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID
72. ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells
73. α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients
74. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow
75. A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic Myeloid Leukemia.
76. Interferon Alpha Alone Is Able to Cure Chronic Myeloid Leukemia In a Small Subset of Patients Despite the Persistence of Leukemic Cells: Experience of Long Follow up After Treatment Discontinuation
77. ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
78. 2010 : le Cancéropôle Grand Sud-Ouest dresse un bilan du premier plan quadriennal et prépare sa stratégie future dans la continuité et dans l’émergence en cohérence avec le Plan Cancer II
79. Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS
80. Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.
81. Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.
82. Ex-Vivo Expanded Peripheral Blood Stem Cells (EVEC) Compared with Un Manipulated Peripheral Blood Stem Cells (PBSC) Autologous Transplantation for Multiple Myeloma: A Pair Match Analysis.
83. Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial
84. Le Cancéropôle Grand Sud-Ouest : les réseaux se renforcent
85. Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission
86. High fluorescence reticulocytes are an indicator of bone marrow recovery after chemotherapy
87. Defensine Alpha1 as a New Marker of Imatinib Resistance in Chronic Myelogenous Leukemia
88. Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre « Stop Imatinib » (STIM) Study
89. Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group
90. Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035
91. Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory
92. Prognosis of Patients with AML Carrying 11Q23/MLL Reciprocal Translocations : A Retrospective Study of 191 Cases from the French AML-Intergroup
93. Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.
94. High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.
95. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
96. Trough Plasma Imatinib Concentrations Are Associated with Both Cytogenetic and Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.
97. AML with 11q23/MLL Abnormalities: A Survey of 146 Cases from French AML Intergroup.
98. Imatinib Mesylate Discontinuation in Patients with Chronic Myelogenous Leukemia in Complete Molecular Remission: An Update Follow Up.
99. A clinical‐scale expansion of mobilized CD34+ hematopoietic stem and progenitor cells by use of a new serum‐free medium
100. Proteasome Inhibition Sensitizes Leukemic Cells to Anthracyclin-Induced Apoptosis by Increasing the Expression of Bim and Bax Pro-Apoptotic Proteins.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.